Agios Pharmaceuticals, Inc.
AGIO
$28.42
$0.431.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 66.05M | 54.03M | 44.79M | 40.88M | 37.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.05M | 54.03M | 44.79M | 40.88M | 37.04M |
| Cost of Revenue | 354.52M | 345.88M | 340.02M | 324.78M | 310.03M |
| Gross Profit | -288.47M | -291.85M | -295.22M | -283.90M | -273.00M |
| SG&A Expenses | 187.06M | 180.28M | 180.37M | 177.63M | 167.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 541.58M | 526.16M | 520.38M | 502.41M | 477.33M |
| Operating Income | -475.53M | -472.13M | -475.59M | -461.53M | -440.29M |
| Income Before Tax | -423.62M | -413.80M | -410.14M | 694.33M | 710.23M |
| Income Tax Expenses | -1.02M | -1.02M | -8.88M | 44.24M | 44.24M |
| Earnings from Continuing Operations | -422.60 | -412.78 | -401.27 | 650.08 | 665.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -422.60M | -412.78M | -401.27M | 650.08M | 665.99M |
| EBIT | -475.53M | -472.13M | -475.59M | -461.53M | -440.29M |
| EBITDA | -470.27M | -466.96M | -470.31M | -456.28M | -434.71M |
| EPS Basic | -7.25 | -7.12 | -6.96 | 11.47 | 11.71 |
| Normalized Basic EPS | -4.54 | -4.46 | -4.45 | -4.30 | -4.15 |
| EPS Diluted | -7.25 | -7.12 | -6.96 | 11.04 | 11.28 |
| Normalized Diluted EPS | -4.54 | -4.46 | -4.45 | -4.28 | -4.12 |
| Average Basic Shares Outstanding | 233.20M | 231.88M | 230.63M | 229.43M | 228.30M |
| Average Diluted Shares Outstanding | 233.20M | 231.88M | 230.63M | 230.93M | 229.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |